

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: 4-6-00

By: Lang Thum

13/D
J. 4/2/00



DOCKET No.: 5325-0122.20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Woodle, et al.

SERIAL No.: 09/139,058

FILED: August 24, 1998

FOR: **METHOD OF TREATMENT OF INFECTED
TISSUES**

EXAMINER: G. Kishore

ART UNIT: 1615

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated December 6, 1999 in the above-identified application, amend the application as follows.

In the Claims

Amend claims 8 and 13 as follows:

8. (Four times Amended) For use in a method of treating a site of systemic infection which is localized at a tissue site other than the fixed macrophages residing in the liver or the spleen, an injectable liposome composition which:

(a) is [composed] comprised of a vesicle-forming [lipids] lipid and [including] between about 1-20 mole percent of an amphipathic vesicle-forming lipid derivatized with a hydrophilic biocompatible polymer selected from the group consisting of polyglycolic acid (PGA), polylactic acid (PLA), a copolymer of PGA and PLA, polyvinyl alcohol and polyethyleneglycol, said polymer being of a size and in a molar amount effective to extend liposome blood circulation time, measured 24 hours after said injection, over that achievable in the absence of the hydrophilic polymer,

(b) is composed of liposomes having a selected mean particle